Copyright
©The Author(s) 2022.
World J Nephrol. Jan 25, 2022; 11(1): 1-12
Published online Jan 25, 2022. doi: 10.5527/wjn.v11.i1.1
Published online Jan 25, 2022. doi: 10.5527/wjn.v11.i1.1
Ref. | Study type | Analyzed specimens | Virus investigated | Analysis method | Positive specimens | ||
No. of cases and tumor type | No. of controls and tissue type | No. of positive cases and tumor type | No. of positive controls and tissue type | ||||
Kim et al[18], 2005 | Retrospective | 73 RCC (22 clear cell; 18 papillary; 20 chromophobe; 10 sarcomatoid; 3 oncocytoma) | 18 non-neoplastic kidneys | EBV | EBER-ISH and PCRs (for EBNA-1 and EBNA-3C) | 5/73 (all sarcomatoid histology) (EBER-ISH)2; 4/73 (all sarcomatoid histology) showed amplification of EBNA-1 | 0/18 |
Neirynck et al[17], 2012 | Case report | 1 RCC1 | 1 peritumoral tissue | BKV | IHC (for SV40 T antigen) | 65%-70% neoplastic cells | < 1% non-neoplastic cells |
Salehipoor et al[19], 2012 | Retrospective | 49 RCC | 16 non-neoplastic kidneys | HPV; EBV; BKV; JCV | Nested PCR (virus DNA) | 7/49 HPV (5 clear cell; 1 chromophobe 1 mixed type) 0 EBV, BKV JCV | 0/16 |
Bulut et al[16], 2013 | Retrospective | 50 RCC | 45 non-neoplastic kidneys | BKV | Nested PCR (BKV DNA) and RT-PCR (BKV mRNA) | 10/50 (Nested PCR) 8/50 (RT-PCR) | 2/45 non neoplastic kidneys (nested PCR, RT-PCR) |
Farhadi et al[20], 2014 | Retrospective | 122 RCC (77 conventional; 26 papillary; 14 chromophobe; 1 collecting duct; 4 unclassified) | 96 peritumoral tissues, 19 non-neoplastic kidneys | HR-HPV | Nested PCR (HR-HPV DNA). IHC (for p16INK4a and L1 Capsid Protein); CSAC-ISH | 37/122 (17 clear-cell; 13 papillary; 4 chromophobe; 3 unclassified) (PCR). 24/118 (IHC for p16INK4a3) 0/118 (IHC for L1 capsid protein); 18/122 (CSAC-ISH) | 4/96 peritumoral tissues; 0/19 non-neoplastic kidneys (PCR); 16/94 peritumoral tissue (IHC for p16INK4a); 0/94 peritumoral tissue (IHC for L1 capsid protein); NA (CSAC-ISH) |
Ref. | Study type | Type of chronic viral infection | Study population | RCC histology | Mean age (yr) | Aim | Main results/conclusions |
Gaughan et al[43], 2008 | Case series | HIV infection | 9 HIV-associated RCC1 | 2 papillary, 1 collecting duct, 6 clear cell | 48 | To describe the risk factors, clinical findings, pathology, and response to therapy in RCC patients infected with HIV | The clinical presentation and behavior of RCC in patients with HIV infection appeared similar to that of the HIV-negative population and that chronic immunosuppression plays a lesser role than age and exposure to risk factors |
Gordon et al[38], 2010 | Retrospective study | HCV infection | 67063 HCV-tested patients: 3057 HCV+ and 64006 HCV- | 17 RCC HCV+: 8 clear cell, 6 papillary, 2 mixed clear cell/papillary, 1 undifferentiated/other; 117 HCV-: 92 clear cell, 43 papillary, 9 mixed clear cell/papillary, 26 undifferentiated/other | 54 in HCV+, 63 in HCV- | To determine whether HCV infection confers an increased risk for developing RCC | RCC was diagnosed in 0.6% (17/3057) of HCV+ and 0.3% (117/64006) of HCV- patients. HCV infection confers a risk for the development of RCC: Overall HR for RCC among HCV patients 1.77 (95% confidence interval, 1.05-2.98; P = 0.0313) |
Wiwanitkit[42], 2011 | Bioinformatics analysis | HCV infection | NA | NA | NA | To assess the cause–outcome relationship between HCV infection and RCC using the bioinformatics network analysis technique | There might be a cause–outcome relationship between HCV infection and RCC via NY-REN-54 (the only one common protein) |
Gonzalez et al[39], 2015 | Prospective study | HCV infection | 140 RCC and 100 colon cancer patients (control) | NA | 56.7 in RCC patients with viremia, 61.8 in aviremic patients | To determine whether chronic HCV is associated with an increased risk of RCC | 11/140 RCC and 1/100 colon cancer patients were HCAB+. Of the HCAB+ patients, 9/11 RCC and 0/1 controls had detectable HCV RNA. In the multivariable logistic regression analysis, being HCV RNA positive was a significant risk factor for RCC (P = 0.043) |
Wijarnpreecha et al[40], 2016 | Systematic review and meta-analysis | HCV infection | 196826 patients from 7 observational studies (4 cohort and 3 case-control studies). Individuals without HCV infection were used as comparators in cohort studies, individuals without RCC as comparators in the cross-sectional and case-control studies | NA | NA2 | To assess the risk of RCC in patients with HCV infection | Significantly increased risk of RCC in HCC+ with the pooled risk ratio of 1.86 (95%CI: 1.11-3.11) |
Ong et al[44], 2016 | Case series | HIV infection | 7 HIV-associated RCC1 | 5 clear cell, 1 papillary, 1 unknown | 56 | To report presentation, management and outcomes of RCC patients with HIV infection | RCC patients with HIV infection should be offered all treatment options in the same manner as the general population |
Tsimafeyeu et al[41], 2020 | Retrospective study | HCV infection | 44 mRCC patients: 22 HCV+, 22 HCV- | Clear cell | 62 in mRCC HCV+, 63 in mRCC HCV- | To evaluate Nivolumab efficacy and safety in mRCC patients with or without chronic HCV infection (OS primary endpoint, PFS, ORR and rate of grade 3–4 adverse events secondary endpoints) | HCV-infected patients had significantly longer OS (27.5 vs 21.7, P = 0.005) and PFS (7.5 vs 4.9, P = 0.013), no difference in ORR. Grade 3–4 adverse events were observed in 5 (23%) HCV+ patients and in 3 (14%) HCV- patients |
- Citation: Bersanelli M, Casartelli C, Buti S, Porta C. Renal cell carcinoma and viral infections: A dangerous relationship? World J Nephrol 2022; 11(1): 1-12
- URL: https://www.wjgnet.com/2220-6124/full/v11/i1/1.htm
- DOI: https://dx.doi.org/10.5527/wjn.v11.i1.1